Sargent Bickham Lagudis LLC Vertex Pharmaceuticals Inc Transaction History
Sargent Bickham Lagudis LLC
- $1.22 Billion
- Q4 2022
A detailed history of Sargent Bickham Lagudis LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Sargent Bickham Lagudis LLC holds 202 shares of VRTX stock, worth $78,204. This represents 0.0% of its overall portfolio holdings.
Number of Shares
202
Previous 202
-0.0%
Holding current value
$78,204
Previous $58,000
-0.0%
% of portfolio
0.0%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding VRTX
# of Institutions
1,810Shares Held
239MCall Options Held
1.95MPut Options Held
1.14M-
Capital World Investors Los Angeles, CA28.7MShares$11.1 Billion1.94% of portfolio
-
Vanguard Group Inc Valley Forge, PA24MShares$9.28 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$8.25 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA16.1MShares$6.24 Billion1.5% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.56 Billion0.2% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $99.4B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...